May 2017 Newsletter Survey
We’d like to know what you think of Dr. Scott Gottlieb, the man chosen by President Trump (and recently confirmed by the US Senate) to head the US Food & Drug Administration (FDA).
Updates on Diabetic Retinopathy from the ADA
The latest position statement from the American Diabetes Association (ADA) recommends improvements in the assessment and treatment of diabetic retinopathy.
More comorbidities and complications with Type 2 diabetes versus Type 1
Maybe Type 2 isn't really "the good" kind of diabetes after all…
BG control in Type 1 Diabetes Improves with Fast-Acting Insulin Aspart
According to a study published online in Diabetes Care on April 11, fast-acting insulin aspart (faster aspart) improved blood glucose control in patients with Type 1 diabetes, as compared to the conventional formulation of the drug, insulin aspart (IAsp). In the United States, insulin aspart is better known as Novo Nordisk's insulin Novolog. In many other countries, it is known as NovoRapid.
My Review of Afrezza Fast Acting Inhaled Insulin
By avoiding the need to absorb through the fat layer below the skin, Afrezza starts working almost immediately, peaks in about 15 minutes, and in most cases, clears in about 2 hours. Now that’s rapid!